JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China

CHALFONT ST. GILES, UK and WUHAN, CHINA – 10 May 2016 –JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China today. JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars(1) and monoclonal antibodies (mAbs)... Read more

JHL Biotech Announces Mechanical Completion of its Wuhan Biopharmaceutical Manufacturing Facility

WUHAN, China and AMERSHAM, England, Feb. 25, 2016 /PRNewswire/ — JHL Biotech (TPEx: 6540) and GE Healthcare’s Life Sciences business (NYSE: GE) are proud to announce mechanical completion of JHL Biotech’s JHL-1 biopharmaceutical manufacturing facility in the Biolake area of Wuhan, China. The campus was built to be compliant with the highest international standards, and after site validation is completed in June... Read more